Vaxcyte, Inc. (PCVX)

Vaxcyte Statistics

Total Valuation

Vaxcyte has a market cap or net worth of $6.37 billion. The enterprise value is $4.75 billion.

Market Cap	6.37B
Enterprise Value	4.75B

Important Dates

The last earnings date was Tuesday, November 4, 2025, after market close.

Earnings Date	Nov 4, 2025
Ex-Dividend Date	n/a

Share Statistics

Vaxcyte has 130.91 million shares outstanding. The number of shares has increased by 19.29% in one year.

Current Share Class	130.91M
Shares Outstanding	130.91M
Shares Change (YoY)	+19.29%
Shares Change (QoQ)	+0.12%
Owned by Insiders (%)	0.77%
Owned by Institutions (%)	99.86%
Float	117.93M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	n/a
Forward PS	n/a
PB Ratio	2.19
P/TBV Ratio	2.20
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Enterprise Valuation

EV / Earnings	n/a
EV / Sales	n/a
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	n/a

Financial Position

The company has a current ratio of 8.83, with a Debt / Equity ratio of 0.03.

Current Ratio	8.83
Quick Ratio	8.56
Debt / Equity	0.03
Debt / EBITDA	n/a
Debt / FCF	n/a
Interest Coverage	n/a

Financial Efficiency

Return on equity (ROE) is -20.83% and return on invested capital (ROIC) is -15.79%.

Return on Equity (ROE)	-20.83%
Return on Assets (ROA)	-15.07%
Return on Invested Capital (ROIC)	-15.79%
Return on Capital Employed (ROCE)	-27.31%
Revenue Per Employee	n/a
Profits Per Employee	-$1.59M
Employee Count	414
Asset Turnover	n/a
Inventory Turnover	n/a

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has decreased by -49.61% in the last 52 weeks. The beta is 1.29, so Vaxcyte's price volatility has been higher than the market average.

Beta (5Y)	1.29
52-Week Price Change	-49.61%
50-Day Moving Average	39.48
200-Day Moving Average	43.62
Relative Strength Index (RSI)	68.76
Average Volume (20 Days)	1,365,430

Short Selling Information

The latest short interest is 8.57 million, so 6.55% of the outstanding shares have been sold short.

Short Interest	8.57M
Short Previous Month	10.01M
Short % of Shares Out	6.55%
Short % of Float	7.27%
Short Ratio (days to cover)	4.95

Income Statement

Revenue	n/a
Gross Profit	n/a
Operating Income	-811.56M
Pretax Income	-657.20M
Net Income	-657.20M
EBITDA	-799.80M
EBIT	-811.56M
Earnings Per Share (EPS)	-$4.84

Balance Sheet

The company has $1.71 billion in cash and $84.44 million in debt, giving a net cash position of $1.63 billion or $12.43 per share.

Cash & Cash Equivalents	1.71B
Total Debt	84.44M
Net Cash	1.63B
Net Cash Per Share	$12.43
Equity (Book Value)	2.89B
Book Value Per Share	22.25
Working Capital	1.57B

Cash Flow

In the last 12 months, operating cash flow was -$542.15 million and capital expenditures -$78.58 million, giving a free cash flow of -$620.73 million.

Operating Cash Flow	-542.15M
Capital Expenditures	-78.58M
Free Cash Flow	-620.73M
FCF Per Share	-$4.74

Margins

Gross Margin	n/a
Operating Margin	n/a
Pretax Margin	n/a
Profit Margin	n/a
EBITDA Margin	n/a
EBIT Margin	n/a
FCF Margin	n/a

Dividends & Yields

Vaxcyte does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-19.29%
Shareholder Yield	-19.29%
Earnings Yield	-10.31%
FCF Yield	-9.74%

Analyst Forecast

The average price target for Vaxcyte is $101.67, which is 108.81% higher than the current price. The consensus rating is "Strong Buy".

Price Target	$101.67
Price Target Difference	108.81%
Analyst Consensus	Strong Buy
Analyst Count	7
Revenue Growth Forecast (5Y)	n/a
EPS Growth Forecast (5Y)	-12.29%

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value	n/a
Lynch Upside	n/a
Graham Number	n/a
Graham Upside	n/a

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

Altman Z-Score	n/a
Piotroski F-Score	1